NasdaqGS:SPRO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Spero Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SPRO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.6%

SPRO

1.6%

US Biotechs

1.6%

US Market


1 Year Return

14.8%

SPRO

22.8%

US Biotechs

4.8%

US Market

Return vs Industry: SPRO underperformed the US Biotechs industry which returned 22.8% over the past year.

Return vs Market: SPRO exceeded the US Market which returned 4.8% over the past year.


Shareholder returns

SPROIndustryMarket
7 Day1.6%1.6%1.6%
30 Day8.5%5.6%2.3%
90 Day83.9%31.2%29.5%
1 Year14.8%14.8%24.0%22.8%7.1%4.8%
3 Yearn/a33.4%29.0%37.1%28.1%
5 Yearn/a0.8%-5.0%67.2%48.6%

Price Volatility Vs. Market

How volatile is Spero Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Spero Therapeutics undervalued compared to its fair value and its price relative to the market?

3.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SPRO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SPRO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SPRO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SPRO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SPRO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SPRO is good value based on its PB Ratio (3.3x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Spero Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

60.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SPRO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SPRO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SPRO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SPRO's revenue (70.5% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: SPRO's revenue (70.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SPRO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Spero Therapeutics performed over the past 5 years?

-23.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SPRO is currently unprofitable.

Growing Profit Margin: SPRO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SPRO is unprofitable, and losses have increased over the past 5 years at a rate of -23.1% per year.

Accelerating Growth: Unable to compare SPRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: SPRO has a negative Return on Equity (-95.98%), as it is currently unprofitable.


Next Steps

Financial Health

How is Spero Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: SPRO's short term assets ($98.0M) exceed its short term liabilities ($22.7M).

Long Term Liabilities: SPRO's short term assets ($98.0M) exceed its long term liabilities ($4.7M).


Debt to Equity History and Analysis

Debt Level: SPRO is debt free.

Reducing Debt: SPRO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SPRO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SPRO has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 22.8% each year.


Next Steps

Dividend

What is Spero Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SPRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SPRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SPRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SPRO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SPRO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Ankit Mahadevia (39yo)

5.33yrs

Tenure

US$1,785,676

Compensation

Dr. Ankit Mahadevia, MD, MBA serves as the Chief Executive Officer and President of Spero Therapeutics, LLC. Dr. Mahadevia Co-founded of Spero Therapeutics, Inc. in 2013 and has been its Chief Executive Of ...


CEO Compensation Analysis

Compensation vs Market: Ankit's total compensation ($USD1.79M) is above average for companies of similar size in the US market ($USD1.35M).

Compensation vs Earnings: Ankit's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Ankit Mahadevia
Co-Founder5.33yrsUS$1.79m0.32% $880.0k
Cristina Larkin
Chief Operating Officer2.83yrsUS$943.29k0.0073% $20.0k
David Melnick
Chief Medical Officer2.5yrsUS$936.29kno data
Stephen DiPalma
Interim CFO & Treasurer0.67yrno datano data
Thomas Parr
Chief Scientific Officer6.25yrsUS$450.89kno data
Sharon Klahre
Senior Director of Investor Relationsno datano datano data
Jay Blackington
Vice President of People Strategy & Culture1.67yrsno datano data
Timothy Keutzer
Chief Development Officer1.08yrsno data0.012% $33.4k
Ian Critchley
Head of Clinical Microbiology2.25yrsno datano data
Susannah Walpole
Head of Clinical Operations2.5yrsno datano data

2.5yrs

Average Tenure

56.5yo

Average Age

Experienced Management: SPRO's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ankit Mahadevia
Co-Founder5.33yrsUS$1.79m0.32% $880.0k
Jean-Francois Formela
Independent Director7.33yrsUS$89.37kno data
Frank Thomas
Independent Director3yrsUS$99.37kno data
Milind Deshpande
Independent Chairmanno dataUS$122.87k0.080% $220.0k
Eric Gordon
Scientific Advisors6.17yrsno datano data
George Drusano
Clinical Advisor6.17yrsno datano data
Steven Gilman
Scientific Advisorno datano datano data
Patrick V. J. Vink
Independent Director4.83yrsUS$97.87kno data
Gordon Archer
Clinical Advisor6.17yrsno datano data
Paul Ambrose
Clinical Advisor6.17yrsno datano data

6.2yrs

Average Tenure

63yo

Average Age

Experienced Board: SPRO's board of directors are considered experienced (6.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.5%.


Top Shareholders

Company Information

Spero Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Spero Therapeutics, Inc.
  • Ticker: SPRO
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$275.359m
  • Shares outstanding: 20.60m
  • Website: https://sperotherapeutics.com

Number of Employees


Location

  • Spero Therapeutics, Inc.
  • 675 Massachusetts Avenue
  • 14th Floor
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SPRONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2017
2HADB (Deutsche Boerse AG)YesCommon StockDEEURNov 2017

Biography

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/03 00:18
End of Day Share Price2020/07/02 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.